The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is patient quality of life superior with CAR T or stem cell transplant?

Dec 13, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Morie Gertz, Mayo Clinic, Rochester, US, answers the question: Is patient quality of life superior with CAR T or stem cell transplant?

Morie Gertz discusses patient quality of life issues comparing CAR T treatment versus stem cell transplant. He describes the associated toxicities of both treatment modalities and explains that treatment is guided by the patient's disease stage e.g. stem cell transplantation is offered early in the treatment pathway, whilst CAR T therapy is mainly offered to patients with very advanced disease. He concludes by describing an upcoming trial that will compare both these treatments as maintenance, where the clear distinction between treatment superiority on quality of life can be made.

Is patient quality of life superior with CAR T or stem cell transplant?